Virus and antibody dynamics in acute west nile virus infection

Journal of Infectious Diseases

Volumn 198, Issue 7, 2008, Pages 984-993

  Busch, Michael P ^a,b   Kleinman, Steven H ^a,i   Tobler, Leslie H ^a   Kamel, Hany T ^e   Norris, Philip J ^a,b   Walsh, Irina ^a   Matud, Jose L ^c   Prince, Harry E ^c   Lanciotti, Robert S ^g   Wright, David J ^h   Linnen, Jeffrey M ^d   Caglioti, Sally ^f  

^a BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Focus Diagnostics Inc   (United States)

^d Gen Probe Incorporated   (United States)

^e Blood Systems Incorporated   (United States)

^f Blood Systems Laboratories   (United States)

^g NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^h WESTAT   (United States)

ⁱ UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; NEUTRALIZING ANTIBODY;

ARTICLE; BLOOD DONOR; BLOOD SAMPLING; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PERSISTENT INFECTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RNA TRANSCRIPTION; SEROCONVERSION; VIREMIA; VIRUS INFECTION; WEST NILE FLAVIVIRUS;

ACUTE DISEASE; ANTIBODIES, VIRAL; BLOOD DONORS; BLOOD TRANSFUSION; HUMANS; NEUTRALIZATION TESTS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; RNA, VIRAL; WEST NILE FEVER; WEST NILE VIRUS;

EID: 51849165090     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/591467     Document Type: Article

References (45)

1. Petersen LR, Marfin AA. West Nile virus: a primer for the clinician. Ann Intern Med 2002; 137:173-9.
2. Petersen LR, Hayes EB. Westward ho? - the spread of West Nile virus. N Engl J Med 2004; 351:2257-9.
3. Watson JT, Pertel PE, Jones RC, et al. Clinical characteristics and functional outcomes of West Nile fever. Ann Intern Med 2004; 141:360-5.
4. Gea-Banacloche J, Johnson RT, Bagic A, Butman JA, Murray PR, Agrawal AG. West Nile virus: pathogenesis and therapeutic options. Ann Intern Med 2004; 140:545-54.
5. Pealer LN, Marfin AA, Petersen LR, et al. Transmission of West Nile Virus through blood transfusion in the United States in 2002. West Nile Virus Transmission Investigation Team. N Engl J Med 2003; 349:1236-45.
6. Dodd RY. Emerging infections, transfusion safety, and epidemiology. New Engl J Med 2003; 349:1205-6.
7. Busch MP, Tobler LH, Saldanha J, et al. Analytical and clinical sensitivity of West Nile virus RNA screening and supplemental assays available in 2003. Transfusion 2005; 45:492-9.
8. Stramer SL, Glynn SA, Kleinman SH, et al. Detection of HIV-1 and HCV infections among antibody-negative U.S. blood donors by nucleic acid amplification testing. NHLBI-REDS NAT Study Group. New Engl J Med 2004; 351:760-8.
9. Custer B, Tomasulo P, Murphy EL, et al. Triggers for switching from minipool testing by nucleic acid testing for West Nile virus: analysis of 2003 data to inform 2004 decision making. Transfusion 2004; 44:1547-54.
10. Kleinman S, Glynn SA, Busch M, et al. The 2003 West Nile virus United States epidemic: the America's Blood Centers experience. NHLBI Retrovirus Epidemiology Study (REDS). Transfusion 2005; 45:469-79.
11. Stramer SL, Fang CT, Foster, GA, et al. West Nile virus among blood donors in the United States, 2003 and 2004. N Engl J Med 2005; 353:451-9.
12. Busch MP, Caglioti S, Robertson EF, et al. Screening the blood supply for West Nile virus RNA by nucleic acid amplification testing. N Engl J Med 2005; 353:460-7.
13. Busch MP, Wright DJ, Custer B, et al. West Nile virus infections projected from blood donor screening data, United States, 2003. Emerg Infect Dis 2006; 12:395-402.
14. Custer B, Busch MP, Marfin AA, Petersen LR. The cost-effectiveness of screening the US blood supply for West Nile virus. Ann Intern Med 2005; 143:486-92.
15. Montgomery SP, Brown JA, Kuehnert M, et al. Transfusion-associated transmission of West Nile virus, United States 2003-2005. Transfusion 2006; 46:2038-46.
16. Centers for Disease Control and Prevention. West Nile virus transmission - South Dakota, 2006. MMWR Morb Mortal Wkly Rep 2007; 56:76-9.
17. Orton SL, Stramer SL, Dodd RY. Self-reported symptoms associated with West Nile virus infection in RNA-positive blood donors. Transfusion 2006; 46:272-7.
18. Martin DA, Biggerstaff BJ, Allen B, Johnson AJ, Lanciotti RS, Roehrig JT. Use of immunoglobulin M cross-reactions in differential diagnosis of human flaviviral encephalitis infections in the United States. Clin Diagn Lab Immunol 2002; 9:544-9.
19. Tardei G, Ruta S, Chitu V, Rossi C, Tsai TF, Cernescu C. Evaluation of immunoglobulin M (IgM) and IgG enzyme immunoassays in serologic diagnosis of West Nile virus infection. J Clin Microbiol 2000; 38:2232-9.
20. Roehrig JT, Nash D, Maldin B, et al. Persistence of virus-reactive serum immunoglobulin M antibody in confirmed West Nile virus encephalitis cases. Emerg Infect Dis 2003; 9:376-9.
21. Prince HE, Hogrefe WR. Detection of West Nile virus (WNV)-specific immunoglobulin M in a reference laboratory setting during the 2002 WNV season in the United States. Clin Diagn Lab Immunol 2003; 10:764-8.
22. Prince HE, Tobler LH, Lape-Nixon M, Foster GA, Stramer SL, Busch MP. Development and persistence of West Nile virus immunoglobulin M(IgM), IgA, and IgG during follow-up of viremic blood donors. J Clin Microbiol 2005; 43:4316-20.
23. Linnen JM, Deras ML, Cline J, et al. Performance evaluation of the Procleix West Nile virus assay on semi-automated and automated systems. J Med Virol 2007; 79:1422-30.
24. Tobler LH, Cameron MJ, Norris PJ, et al. Interferon and interferon-induced chemokine expression is associated with control of acute viremia in West Nile virus-infected blood donors. J Infect Dis 2008; 198:979-83 [in this issue].
25. Lanteri M, Heitman J, Owen R, et al. Comprehensive analysis of West Nile virus-specific T cell responses in human infection. J Infect Dis 2008; 197:1296-306.
26. Flavivirus (West Nile) IgM Capture ELISA [package insert]. Cypress, CA: Focus Technologies. Available at: http://www.focustechnologies.com. Accessed 27 September 2004.
27. Flavivirus (West Nile) ELISA IgG [package insert]. Cypress, CA: Focus Technologies. Available at: http://www.focustechnologies.com. Accessed 27 September 2004.
28. Specter S, Hodinka RL, Wiedbrauk DL, Young S. Diagnosis of viral infections. In: Richman DD, Whitley RJ, Hayden FG, eds. Clinical virology. Washington, DC: ASM Press, 2002:263-4.
29. Lindsey JC, Ryan LM. Tutorial in biostatistics methods for interval-censored data. Stat Med 1998; 17:219-38.
30. Cantor A. SAS survival analysis techniques for medical research. 2nd ed. Cary, NC: SAS Publishing, 2003.
31. Turnbull BW. The empirical distribution function from arbitrarily grouped, censored and truncated data. J Royal Statistical Soc Series B 1976; 38:290-5.
32. Inheiro JC, Bates DM. Fitting linear mixed-effects models. In: Pinheiro JC, Bates DM, eds. Mixed-effects models in S and S-plus. New York, NY: Springer-Verlag, 2002:133-97.
33. R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2006. Available at: http://www.R-project.org. Accessed 14 July 2008.
34. Southam CM, Moore AE. Induced virus infections in man by the Egypt isolates of West Nile virus. Am J Trop Med Hyg 1954; 3:19-50.
35. Daffis S, Samuel MA, Keller BC, Gale M Jr, Diamond MS. Cell-specific IRF-3 responses protect against West Nile virus infection by interferon-dependent and -independent mechanisms. PLoS Pathogens 2007; 3:e106.
36. Bourne N, Scholle F, Silva MC, et al. Early production of type I interferon during West Nile virus infection: role for lymphoid tissues in IRF3-independent interferon production. J Virol 2007; 81:9100-8.
37. Shrestha B, Wang T, Samuel MA, et al. Gamma interferon plays a crucial early antiviral role in protection against West Nile virus infection. J Virol 2006; 80:5338-48.
38. Rios M, Daniel S, Chancey C, Hewlett IK, Stramer SL. West Nile virus adheres to human red blood cells in whole blood. Clin Infect Dis 2007; 45:181-6.
39. Hannigan A, O'Mullane DM, Barry D, Schafer F, Roberts AJ. A reanalysis of a cries clinical trial by survival analysis. J Dent Res 2001; 80:427-31.
40. Flandre P, Alcais A, Descamps D, Morand-Joubert L, Joly V. Estimating and comparing reduction in HIV-1 RNA in clinical trials using methods for interval censored data. J Acquir Immune Defic Syndr 2004; 35:286-92.
41. Breastfeeding and HIV International Transmission Study Group. Late postnatal transmission of HIV-1 in breast-fed children: an individual patent data meta-analysis. J Infect Dis 2004; 189:2154-66.
42. Tilley PAG, Fox JD, Jayarman GC, Preiksaitas JK. Nucleic acid testing for West Nile virus RNA in plasma enhances rapid diagnosis of acute infection in symptomatic patients. J Infect Dis 2006; 193:1361-4.
43. Centers for Disease Control and Prevention. Transfusion-associated transmission of West Nile virus - Arizona, 2004. MMWR Morb Mortal Wkly Rep 2004; 53:842-4.
44. Stramer SL, Brodsky JP, Caglioti S, Strong DM. Confirmation of infection among donors identified by minipool and individual donation nucleic acid testing for West Nile virus in the United States from 2003-2005 [abstract]. Transfusion 2006; 46(Suppl):2A.
45. Center for Biologics Evaluation and Research, Food and Drug Administration. Guidance for industry: assessing donor suitability and blood product safety in cases of known or suspected West Nile virus Infection. June 2005. Available at: http://www.fda.gov/cber/gdlns/wnvguid.htm. Accessed 14 July 2008.